Developer docs
API playgroundTry for free, no card

Search company profiles

Strand Therapeutics

Full company profile

uuid00003iv

Namestring
Strand Therapeutics
Legal namestring
Strand Therapeutics Inc.
Websiteurl
strandtx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancer and autoimmune disease, founded in 2017 by MIT synthetic biologists and headquartered in Boston, Massachusetts. Its core offering is the Strand Signal Stack, an integrated platform that combines three proprietary modules: SignalPath lipid nanoparticles for targeted delivery beyond the liver, SignalLock RNA for microRNA-sensing tissue-selective expression, and SignalScript self-replicating and circular RNA for potency and durability. AI/ML-driven design and a proprietary microRNA database spanning hundreds of tissues feed the platform, which is anchored by an exclusive license to foundational synthetic biology IP from MIT's Synthetic Biology Center.

Strand's pipeline comprises three named drug candidates: STX-001, a self-replicating mRNA expressing IL-12 via intratumoral injection, which received FDA IND clearance in January 2024, dosed its first patient in May 2024, and reported complete patient responses in initial Phase 1 data at ASCO 2025; STX-003, a systemically delivered, SignalLock-encrypted IL-12 mRNA for NSCLC and solid tumors expected to enter the clinic in 2026; and STX-005, a circular mRNA construct for in vivo CAR-T in autoimmune disease and hematological malignancies. Strategic pharma investors including Eli Lilly, Regeneron, and Amgen have participated across funding rounds alongside BeiGene, which signed a co-development agreement for solid tumor immuno-oncology in 2021.

The business model is enterprise B2B platform licensing and co-development rather than direct product commercialization, with the company leveraging major industry conferences (J.P. Morgan Healthcare Conference, ASGCT, ASCO, AACR, SITC), peer-reviewed publications in Nature-family journals, and a partnering@strandtx.com business development channel to drive biopharma partnerships. Strand has raised approximately $153M in Series B (August 2025), $97M in total Series A funding (2021-2022), and multiple NIH SBIR grants, with 101-250 employees and no commercial product revenue at present.

Short descriptiontext

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors and autoimmune disease via its Signal Stack platform, serving biopharma partners through co-development and licensing deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
programmable mRNA therapeutics, lipid nanoparticle delivery, self-replicating RNA therapeutics, immuno-oncology drug development, in vivo CAR-T therapy
Industry4 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Programmable mRNA Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnerships & Licensing
TypeLicensing Royalties
Description

Strand is a clinical-stage biotechnology company that has not yet commercialized products. The implied revenue model is based on pharmaceutical partnerships and licensing deals, exemplified by the BeiGene agreement to co-develop solid tumor immuno-oncology therapeutics using Strand's multi-functional mRNA technology. Revenue would derive from upfront payments, milestone payments, and royalties on partnered programs.

strandtx.com
2Grant & Non-Dilutive Funding
TypeLicensing Royalties
Description

Strand has supplemented equity financing with non-dilutive funding, including Phase I NIH SBIR contracts to develop mRNA-based CAR-T immunotherapy for Non-Hodgkin's Lymphoma (~ $400,000) and additional SBIR grants for melanoma and breast cancer programs.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Strand Signal Stack
Description

End-to-end mRNA technology platform comprising SignalPath LNPs (targeted delivery), SignalLock RNA (microRNA-sensing selectivity), and SignalScript RNA (potent self-replicating and circular RNA).

strandtx.com
+3 more records
Core offering1 text field

Strand Therapeutics is a clinical-stage biotechnology company that develops programmable mRNA therapeutics for cancer and autoimmune diseases, anchored by its Strand Signal Stack platform. The platform integrates three proprietary technologies — SignalPath LNPs for tissue-targeted delivery, SignalLock RNA microRNA-sensing encryption for safety, and SignalScript self-replicating/circular RNA for potency and durability — and powers a pipeline of drug candidates including STX-001 (intratumoral IL-12 for solid tumors, in Phase 1), STX-003 (systemic IL-12 for solid tumors, entering clinic 2026), and STX-005 (in vivo CAR-T for autoimmune and hematological malignancies). Strand monetizes through biopharma partnerships and licensing, exemplified by its BeiGene co-development agreement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Complete patient responses observed in Phase 1 dose escalation of STX-001 in advanced solid tumors (intratumoral delivery); near-clear scans at week 30 vs metastatic lesions at week 12
+2 more records
Product overview1 text field

Strand Therapeutics is a clinical-stage biotechnology company whose offering is structured as a platform-plus-modules architecture built around a single core platform — the Strand Signal Stack — that integrates three named modules (SignalPath LNPs for targeted delivery, SignalLock RNA for tissue-selective safety, and SignalScript RNA for potency and durability). This core platform powers a pipeline of three named therapeutic drug candidates (STX-001, STX-003, and STX-005) targeting cancers and autoimmune diseases, with STX-001 in Phase 1 clinical trials and STX-003 expected to enter the clinic in 2026. Together, the Signal Stack platform modules produce a plug-and-play delivery system that generates Strand's pipeline of self-replicating mRNA and circular RNA therapeutics for solid tumors, hematological malignancies, and autoimmune indications.

Product and service4 records
1Strand Signal Stack
CategoryProgrammable mRNA platform / technology suite
2STX-001
CategoryPipeline drug candidate — solid tumors (intratumoral IL-12)
3STX-003
CategoryPipeline drug candidate — solid tumors (systemic IL-12)
4STX-005
CategoryPipeline drug candidate — in vivo CAR-T (autoimmune and hematological malignancies)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Jeb Keiper (Independent Board Director)
Strategic tierStrategicTypeOthersAnnounced on2025-12-02
Description

Jeb Keiper was appointed to Strand Therapeutics' Board of Directors in December 2025. He previously served as President and CEO of Nimbus Therapeutics (2018-2025), overseeing $650M+ in equity funding and $7B+ in deal value. He also serves on boards of Cardurion Pharmaceuticals and ROME Therapeutics.

businesswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-11
Description

Strand Therapeutics entered into an agreement with BeiGene to develop solid tumor immuno-oncology therapeutics based on Strand's next-generation, multi-functional mRNA technology. The collaboration leverages Strand's programmable mRNA platform to advance novel immuno-oncology treatments.

3Bristol-Myers Squibb (BMS)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Strand was a 2018 winner of BMS's 'Golden Ticket' contest, which awarded lab space to innovative local startups as part of BMS's effort to increase visibility in the Cambridge/Boston life science community and support the opening of BMS' Cambridge R&D site.

strandtx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage in vivo CRISPR/Cas9 gene editing company with LNP and AAV delivery platforms across oncology, rare disease, and autoimmune indications. Comparable as a nucleic acid therapeutic developer with LNP delivery expertise overlapping Strand's SignalPath LNPs, though using gene editing rather than mRNA.

TypeOthers
Description

Privately held biotechnology company developing lipid nanoparticle delivery systems for nucleic acid therapeutics, including mRNA and gene editing payloads. Comparable as an LNP technology provider and enabler in the same delivery ecosystem that Strand's SignalPath LNPs compete within; serves multiple mRNA developers including partners of Moderna and BioNTech.

3Translate Bio (Sanofi)
TypeBroad incumbent
Description

mRNA therapeutics developer acquired by Sanofi in 2021, focused on pulmonary and other rare disease indications using lipid nanoparticle delivery. Comparable as a clinical-stage mRNA company with LNP delivery expertise overlapping with Strand's SignalPath LNPs, now operating within Sanofi's broader pipeline.

TypeDirect peer
Description

Clinical-stage programmable mRNA therapeutics company engineering omega epigenetic controllers via mRNA delivery. Direct peer in the programmable mRNA category with similar tissue-selective expression concept via engineered RNA circuits, focused on oncology and rare disease.

5Laronde (now Ascidian Therapeutics)
TypeEmerging player
Description

Developer of engineered circular RNA (eRNA) therapeutics founded by Flagship Pioneering. Comparable as an emerging programmable RNA player whose circular RNA modality overlaps with Strand's SignalScript RNA; now operating as Ascidian Therapeutics with a focus on RNA editing for genetic diseases.

TypeDirect peer
Description

Clinical-stage mRNA therapeutics company developing self-replicating and conventional mRNA platforms with proprietary LNP delivery. Direct comparable because both pursue self-amplifying mRNA for rare diseases and oncology, including STARR mRNA technology overlapping with Strand's SignalScript RNA.

TypeEmerging player
Description

Clinical-stage in vivo gene editing company using LNP delivery and base editing for cardiovascular disease. Comparable as an LNP-delivered nucleic acid therapeutic developer; both companies rely on lipid nanoparticle delivery beyond the liver, though Strand focuses on mRNA rather than gene editing.

TypeBroad incumbent
Description

Largest publicly traded mRNA therapeutics company with broad pipeline across infectious disease, oncology, and rare diseases. Direct comparable because both companies develop mRNA-based therapeutics, though Moderna operates at vastly greater scale and across multiple modalities beyond Strand's programmable mRNA focus.

TypeBroad incumbent
Description

Global mRNA leader with oncology, infectious disease, and immuno-oncology programs. Comparable to Strand because both pursue mRNA-based cancer therapeutics, but BioNTech is substantially larger and more diversified, including FixVac and individualized neoantigen approaches.

TypeDirect peer
Description

Clinical-stage biotechnology company developing circular RNA (oRNA) therapeutics with proprietary LNP delivery for oncology, autoimmune disease, and genetic disorders. Direct peer because Strand's SignalScript RNA and Orna's oRNA both develop circular RNA payloads with overlapping target indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Strand Therapeutics

Programmable mRNA Therapeuticsstrandtx.com

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors and autoimmune disease via its Signal Stack platform, serving biopharma partners through co-development and licensing deals.

What Strand Therapeutics does

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancer and autoimmune disease, founded in 2017 by MIT synthetic biologists and headquartered in Boston, Massachusetts. Its core offering is the Strand Signal Stack, an integrated platform that combines three proprietary modules: SignalPath lipid nanoparticles for targeted delivery beyond the liver, SignalLock RNA for microRNA-sensing tissue-selective expression, and SignalScript self-replicating and circular RNA for potency and durability. AI/ML-driven design and a proprietary microRNA database spanning hundreds of tissues feed the platform, which is anchored by an exclusive license to foundational synthetic biology IP from MIT's Synthetic Biology Center.

Strand's pipeline comprises three named drug candidates: STX-001, a self-replicating mRNA expressing IL-12 via intratumoral injection, which received FDA IND clearance in January 2024, dosed its first patient in May 2024, and reported complete patient responses in initial Phase 1 data at ASCO 2025; STX-003, a systemically delivered, SignalLock-encrypted IL-12 mRNA for NSCLC and solid tumors expected to enter the clinic in 2026; and STX-005, a circular mRNA construct for in vivo CAR-T in autoimmune disease and hematological malignancies. Strategic pharma investors including Eli Lilly, Regeneron, and Amgen have participated across funding rounds alongside BeiGene, which signed a co-development agreement for solid tumor immuno-oncology in 2021.

The business model is enterprise B2B platform licensing and co-development rather than direct product commercialization, with the company leveraging major industry conferences (J.P. Morgan Healthcare Conference, ASGCT, ASCO, AACR, SITC), peer-reviewed publications in Nature-family journals, and a partnering@strandtx.com business development channel to drive biopharma partnerships. Strand has raised approximately $153M in Series B (August 2025), $97M in total Series A funding (2021-2022), and multiple NIH SBIR grants, with 101-250 employees and no commercial product revenue at present.

Strand Therapeutics firmographics

Firmographics
Name
Strand Therapeutics
Legal name
Strand Therapeutics Inc.
Website
https://strandtx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors and autoimmune disease via its Signal Stack platform, serving biopharma partners through co-development and licensing deals.
Ownership category
akta.pro rank

Strand Therapeutics industry classification

Industry
Product category
Programmable mRNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Programmable mRNA therapeutics
  • Lipid nanoparticle delivery
  • Self-replicating RNA therapeutics
  • Immuno-oncology drug development
  • In vivo CAR-T therapy

Where Strand Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Strand Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Strategic Partnerships & Licensing: Strand is a clinical-stage biotechnology company that has not yet commercialized products. The implied revenue model is based on pharmaceutical partnerships and licensing deals, exemplified by the BeiGene agreement to co-develop solid tumor immuno-oncology therapeutics using Strand's multi-functional mRNA technology. Revenue would derive from upfront payments, milestone payments, and royalties on partnered programs.
  2. Grant & Non-Dilutive Funding: Strand has supplemented equity financing with non-dilutive funding, including Phase I NIH SBIR contracts to develop mRNA-based CAR-T immunotherapy for Non-Hodgkin's Lymphoma (~ $400,000) and additional SBIR grants for melanoma and breast cancer programs.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Strand Therapeutics product offering

Product offering

Core offering

Strand Therapeutics is a clinical-stage biotechnology company that develops programmable mRNA therapeutics for cancer and autoimmune diseases, anchored by its Strand Signal Stack platform. The platform integrates three proprietary technologies — SignalPath LNPs for tissue-targeted delivery, SignalLock RNA microRNA-sensing encryption for safety, and SignalScript self-replicating/circular RNA for potency and durability — and powers a pipeline of drug candidates including STX-001 (intratumoral IL-12 for solid tumors, in Phase 1), STX-003 (systemic IL-12 for solid tumors, entering clinic 2026), and STX-005 (in vivo CAR-T for autoimmune and hematological malignancies). Strand monetizes through biopharma partnerships and licensing, exemplified by its BeiGene co-development agreement.

Product overview

Strand Therapeutics is a clinical-stage biotechnology company whose offering is structured as a platform-plus-modules architecture built around a single core platform — the Strand Signal Stack — that integrates three named modules (SignalPath LNPs for targeted delivery, SignalLock RNA for tissue-selective safety, and SignalScript RNA for potency and durability). This core platform powers a pipeline of three named therapeutic drug candidates (STX-001, STX-003, and STX-005) targeting cancers and autoimmune diseases, with STX-001 in Phase 1 clinical trials and STX-003 expected to enter the clinic in 2026. Together, the Signal Stack platform modules produce a plug-and-play delivery system that generates Strand's pipeline of self-replicating mRNA and circular RNA therapeutics for solid tumors, hematological malignancies, and autoimmune indications.

Differentiator

Problem solved

Functional benefit

Brands

  • Strand Signal Stack: End-to-end mRNA technology platform comprising SignalPath LNPs (targeted delivery), SignalLock RNA (microRNA-sensing selectivity), and SignalScript RNA (potent self-replicating and circular RNA).
  • SignalPath LNPs
  • SignalLock RNA
  • SignalScript RNA

Products and services

  • Strand Signal Stack
  • STX-001
  • STX-003
  • STX-005

Quantifiable outcome

  • Complete patient responses observed in Phase 1 dose escalation of STX-001 in advanced solid tumors (intratumoral delivery); near-clear scans at week 30 vs metastatic lesions at week 12
  • +2 more outcomes

Companies that use Strand Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Strand Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Strand Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic, flagship and minor.

  • Jeb Keiper (Independent Board Director)strategicOthers · 2 December 2025Jeb Keiper was appointed to Strand Therapeutics' Board of Directors in December 2025. He previously served as President and CEO of Nimbus Therapeutics (2018-2025), overseeing $650M+ in equity funding and $7B+ in deal value. He also serves on boards of Cardurion Pharmaceuticals and ROME Therapeutics.
  • BeiGeneflagshipStrategic or Co-development Partner · 11 January 2021Strand Therapeutics entered into an agreement with BeiGene to develop solid tumor immuno-oncology therapeutics based on Strand's next-generation, multi-functional mRNA technology. The collaboration leverages Strand's programmable mRNA platform to advance novel immuno-oncology treatments.
  • Bristol-Myers Squibb (BMS)minorGTM or Marketing PartnerStrand was a 2018 winner of BMS's 'Golden Ticket' contest, which awarded lab space to innovative local startups as part of BMS's effort to increase visibility in the Cambridge/Boston life science community and support the opening of BMS' Cambridge R&D site.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Strand Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company with LNP and AAV delivery platforms across oncology, rare disease, and autoimmune indications. Comparable as a nucleic acid therapeutic developer with LNP delivery expertise overlapping Strand's SignalPath LNPs, though using gene editing rather than mRNA.
  • Translate Bio (Sanofi): mRNA therapeutics developer acquired by Sanofi in 2021, focused on pulmonary and other rare disease indications using lipid nanoparticle delivery. Comparable as a clinical-stage mRNA company with LNP delivery expertise overlapping with Strand's SignalPath LNPs, now operating within Sanofi's broader pipeline.
  • Moderna: Largest publicly traded mRNA therapeutics company with broad pipeline across infectious disease, oncology, and rare diseases. Direct comparable because both companies develop mRNA-based therapeutics, though Moderna operates at vastly greater scale and across multiple modalities beyond Strand's programmable mRNA focus.
  • BioNTech: Global mRNA leader with oncology, infectious disease, and immuno-oncology programs. Comparable to Strand because both pursue mRNA-based cancer therapeutics, but BioNTech is substantially larger and more diversified, including FixVac and individualized neoantigen approaches.

Others

  • Acuitas Therapeutics: Privately held biotechnology company developing lipid nanoparticle delivery systems for nucleic acid therapeutics, including mRNA and gene editing payloads. Comparable as an LNP technology provider and enabler in the same delivery ecosystem that Strand's SignalPath LNPs compete within; serves multiple mRNA developers including partners of Moderna and BioNTech.

Direct peers

  • Omega Therapeutics: Clinical-stage programmable mRNA therapeutics company engineering omega epigenetic controllers via mRNA delivery. Direct peer in the programmable mRNA category with similar tissue-selective expression concept via engineered RNA circuits, focused on oncology and rare disease.
  • Arcturus Therapeutics: Clinical-stage mRNA therapeutics company developing self-replicating and conventional mRNA platforms with proprietary LNP delivery. Direct comparable because both pursue self-amplifying mRNA for rare diseases and oncology, including STARR mRNA technology overlapping with Strand's SignalScript RNA.
  • Orna Therapeutics: Clinical-stage biotechnology company developing circular RNA (oRNA) therapeutics with proprietary LNP delivery for oncology, autoimmune disease, and genetic disorders. Direct peer because Strand's SignalScript RNA and Orna's oRNA both develop circular RNA payloads with overlapping target indications.

Emerging players

  • Laronde (now Ascidian Therapeutics): Developer of engineered circular RNA (eRNA) therapeutics founded by Flagship Pioneering. Comparable as an emerging programmable RNA player whose circular RNA modality overlaps with Strand's SignalScript RNA; now operating as Ascidian Therapeutics with a focus on RNA editing for genetic diseases.
  • Verve Therapeutics: Clinical-stage in vivo gene editing company using LNP delivery and base editing for cardiovascular disease. Comparable as an LNP-delivered nucleic acid therapeutic developer; both companies rely on lipid nanoparticle delivery beyond the liver, though Strand focuses on mRNA rather than gene editing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Strand Therapeutics social profiles

Digital presence

Strand Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Strand Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

Strand Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Strand Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strand Therapeutics

What does Strand Therapeutics do?

Strand Therapeutics is a clinical-stage biotechnology company that develops programmable mRNA therapeutics for cancer and autoimmune diseases, anchored by its Strand Signal Stack platform. The platform integrates three proprietary technologies — SignalPath LNPs for tissue-targeted delivery, SignalLock RNA microRNA-sensing encryption for safety, and SignalScript self-replicating/circular RNA for potency and durability — and powers a pipeline of drug candidates including STX-001 (intratumoral IL-12 for solid tumors, in Phase 1), STX-003 (systemic IL-12 for solid tumors, entering clinic 2026), and STX-005 (in vivo CAR-T for autoimmune and hematological malignancies). Strand monetizes through biopharma partnerships and licensing, exemplified by its BeiGene co-development agreement.

Is Strand Therapeutics a public or private company?

Strand Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Strand Therapeutics founded?

Strand Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Strand Therapeutics based?

Strand Therapeutics is headquartered in Boston, United States, in the North America region.

How does Strand Therapeutics make money?

Two revenue lines are on record. Strategic Partnerships & Licensing is the primary driver. The others are grant & Non-Dilutive Funding.

Who are Strand Therapeutics's main competitors?

Broad incumbents on record are Intellia Therapeutics, Translate Bio (Sanofi), Moderna and BioNTech. Acuitas Therapeutics is listed as an others. Direct peers are Omega Therapeutics, Arcturus Therapeutics and Orna Therapeutics. Emerging players are Laronde (now Ascidian Therapeutics) and Verve Therapeutics.

Does Strand Therapeutics have an API?

No public API is recorded for Strand Therapeutics.

What industry is Strand Therapeutics in?

Strand Therapeutics's product category is Programmable mRNA Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The New York TimesFearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share NothingU.S. biotech firms are adopting secrecy to prevent Chinese rivals from exploiting their discoveries. Alnylam, Strand Therapeutics, and Curie.Bio have policies to withhold unpublished data, avoid presentations, and delay patent filings. The shift reflects concerns that well-funded Chinese companies will quickly develop or duplicate new drugs.Business Wire BlogStrand Therapeutics to Present Updated STX-001 Clinical Data Highlighting Durable, Systemic Anti-Tumor Activity, and Showcase STX-003 Trial Design at SITC 2026Strand Therapeutics will present updated Phase I data on STX-001, showing durable systemic anti-tumor activity in advanced melanoma, and a poster on ASCENT-1, its Phase I trial of STX-003. The STX-001 abstract was among the top 150 at SITC 2026, and first-patient dosing for ASCENT-1 was announced on October 28, 2026.Business Wire BlogStrand Therapeutics Doses First Patients with STX-003, a Systemic Programmable mRNA Therapy Designed for Tumor-Selective ActivationStrand Therapeutics dosed the first patients with STX-003, a systemic programmable mRNA therapy expressing IL-12, in the ASCENT-1 Phase 1 trial. The therapy uses SignalLock circuitry to restrict IL-12 expression to tumors, aiming to overcome systemic toxicity. The trial is evaluating safety, pharmacology, and preliminary anti-tumor activity.Labiotech.euEight in vivo CAR T biotechs to follow closelyEight in vivo CAR-T biotechs are profiled, including Umoja Biopharma, Vyriad, CPTx, Legend, Strand, Alaya.bio, AAVivo, and Create Medicines. Their lead candidates target CD19, BCMA, or other antigens, with some in clinical trials. Big pharma is acquiring these companies for billions.The Blog of Author Tim FerrissThe Tim Ferriss Show Transcripts: Tim’s Founder Kitchen — From Brainstorm to the President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics) (#868)Strand Therapeutics CEO Jake Becraft explains the company's programmable genetic medicine platform, which delivers RNA messages to cells to correct protein deficiencies or treat cancer. He cites a melanoma patient with visceral metastases who showed no detectable lesions 18 months after treatment, and notes the company is among the first to demonstrate such an abscopal response in deep organ metastases.BioSpaceStrand Therapeutics Appoints Kunal Bhatia as Chief Financial OfficerStrand Therapeutics appointed Kunal Bhatia as Chief Financial Officer, bringing 15 years of investment banking experience. The appointment follows a $153 million Series B and initial Phase 1 data for STX-001. Bhatia will support the company's clinical entry for STX-003 in mid-2026.ContractpharmaStrand Therapeutics Appoints Kunal Bhatia as Chief Financial OfficerStrand Therapeutics appointed Kunal Bhatia as Chief Financial Officer, bringing 15 years of investment banking experience. He previously served as interim CFO and Chief Business Officer for private life sciences companies and was a Managing Director at Cowen. The company is entering its next growth phase with clinical momentum and a growing pipeline.Business Wire BlogStrand Therapeutics Appoints Kunal Bhatia as Chief Financial OfficerStrand Therapeutics appointed Kunal Bhatia as Chief Financial Officer, bringing 15 years of investment banking experience. The appointment follows a $153 million Series B led by Kinnevik and initial Phase 1 data for STX-001. Bhatia expects to support the company's clinical entry for STX-003 in mid-2026.FiercePharma‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and ChinaStrand Therapeutics CEO Jake Becraft has warned Congress that outdated FDA Investigational New Drug regulations and soaring costs—now exceeding $20 million total to reach first-in-human trials, up from projected costs of $50,000-$100,000 per patient when he founded the company—are driving early-stage clinical research away from the U.S. to China and Australia, which offer faster, cheaper pathways averaging 220 days versus the FDA's 380-day IND review. Becraft is calling for a concerted industry-government effort to modernize chemistry, manufacturing and controls requirements and re-industrialize small-scale manufacturing infrastructure, drawing parallels to China's rare earth playbook in electric vehicles where strategic industrial policy enabled supply chain dominance.FierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and ChinaStrand Therapeutics CEO Jake Becraft testified before the U.S. House Select Committee on China that outdated FDA Investigational New Drug (IND) regulations are forcing small biotechs to conduct first-in-human trials abroad, with costs to reach clinical starting line exceeding $20 million. He warned that the regulatory framework treats Phase 1 drugs as if ready for commercial launch, with an average FDA review taking 380 days versus 220 days in China. Becraft is calling for an industry-government initiative to modernize CMC requirements and re-industrialize small-scale manufacturing, arguing the U.S. risks losing its biomedical industrial capacity to China using the same playbook that disadvantaged Western automakers in the rare earth supply chain.